Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Islasertib,Dofetilide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Thryv Receives FDA Orphan Designation for LQT-1213 in Long QT Syndrome
Details : LQT-1213 is a novel, first-in-class SGK1 inhibitor that the USFDA granted Orphan Drug Designation for the treatment of Long QT Syndrome.
Brand Name : LQT-1213
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2024
Lead Product(s) : Islasertib,Dofetilide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?